Royal Bank of Canada
FBRX

Royal Bank of Canada’s Forte Biosciences FBRX Stock Holding History

Royal Bank of Canada’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Sell
13,322
-67
-0.5% -$1.59K ﹤0.01% 4750
2026
Q1 		$346K Buy
13,389
+1,403
+12% +$40.4K ﹤0.01% 4381
2025
Q4 		$327K Buy
11,986
+733
+7% +$12.9K ﹤0.01% 4473
2025
Q3 		$169K Buy
11,253
+2,019
+22% +$23.3K ﹤0.01% 5191
2025
Q2 		$119K Buy
9,234
+5,892
+176% +$50.7K ﹤0.01% 5526
2025
Q1 		$26K Sell
3,342
-442
-12% -$5.22K ﹤0.01% 5823
2024
Q4 		$86K Buy
+3,784
New +$45K ﹤0.01% 5419
2024
Q3 		– Sell
-5
Closed – – 7014
2024
Q2 		$0 Hold
5
– – ﹤0.01% 7194
2024
Q1 		$0 Buy
+5
New +$87 ﹤0.01% 7170
2023
Q3 		– Sell
-6
Closed – – 7217
2023
Q2 		$0 Sell
6
-1
-14% -$26 ﹤0.01% 7369
2023
Q1 		$0 Hold
7
– – ﹤0.01% 7176
2022
Q4 		$0 Sell
7
-2
-22% -$51 ﹤0.01% 7367
2022
Q3 		$0 Buy
9
+2
+29% +$64 ﹤0.01% 7561
2022
Q2 		$0 Sell
7
-46
-87% -$1.46K ﹤0.01% 7466
2022
Q1 		$2K Sell
53
-69
-57% -$2.61K ﹤0.01% 7475
2021
Q4 		$7K Buy
122
+76
+165% +$5.11K ﹤0.01% 7143
2021
Q3 		$4K Buy
46
+15
+48% +$8.31K ﹤0.01% 7192
2021
Q2 		$26K Buy
+31
New +$27.9K ﹤0.01% 6420
2020
Q4 		– Sell
-1
Closed -$1K – 7125
2020
Q3 		$1K Sell
1
-2
-67% -$1.33K ﹤0.01% 6419
2020
Q2 		$1K Sell
3
-15
-83% -$6.7K ﹤0.01% 6415
2020
Q1 		$8K Buy
+18
New +$7.03K ﹤0.01% 5896
2018
Q4 		– Sell
-1
Closed -$5K – 6858
2018
Q3 		$5K Buy
+1
New +$3.81K ﹤0.01% 6253
2018
Q2 		– Hold
0
– – – 6348
2018
Q1 		– Sell
-83
Closed -$384K – 6466
2017
Q4 		$320K Buy
83
+81
+4,050% +$323K ﹤0.01% 4130
2017
Q3 		$7K Buy
+2
New +$8.91K ﹤0.01% 6353
2017
Q2 		– Hold
0
– – – 6616

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Royal Bank of Canada's FBRX Position: Q2 2026 in Review

Royal Bank of Canada reduced its Forte Biosciences (FBRX) stake by 0.5% in Q2 2026, selling an estimated $1.59K and leaving 13,322 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #4750.

Royal Bank of Canada first reported a position in FBRX in Q3 2017 and has held it in 24 quarters since. The position peaked at $346K in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Royal Bank of Canada held 13,322 shares of Forte Biosciences worth $283K as of Q2 2026.
  • Royal Bank of Canada sold 67 Forte Biosciences shares in Q2 2026, an estimated $1.59K.
  • Forte Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4750 holding.
  • Royal Bank of Canada first reported a position in Forte Biosciences in Q3 2017 and has held it in 24 quarters since.
  • Royal Bank of Canada's Forte Biosciences position peaked at $346K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.